Technological Advances Facilitating Research Across Preclinical Disease Models

Technological Advances Facilitating Research Across Preclinical Disease Models

Bioengineering Innovations in Preclinical Research

RELEASE DATE
24-Jun-2020
REGION
Global
Deliverable Type
Technology Research
Research Code: D98E-01-00-00-00
SKU: HC03308-GL-TR_24522
AvailableYesPDF Download

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03308-GL-TR_24522

$4,950.00

$3,712.50save 25 %

DownloadLink
ENQUIRE NOW

Description

The key focus of this research has been outlined as below:
1. Technology benchmarking and roadmap, market trends, capabilities, and applications targeted: Build a robust strategy by defining the universe of preclinical disease models opportunities and setting key priorities
2. Stakeholder activities, influence, industry initiatives: Evaluate opportunities by describing the main participants in the industry, analyzing potential outcomes and generating competitive intelligence
3. Investment environment and funding support: Support execution by connecting specific strategies with milestones, targets, owners, and deadlines based in funding and investments
4. Industry evolution and business analytics: Preclinical disease models overall industry evolution and business models

Table of Contents

1.1 Research Focus

1.2 Research Scope

1.3 Analysis Framework

1.4 Research Methodology

2.1 Technology Expertise

2.2 Methods, Strategies and Tools

2.3 Targets, Molecules and Biology

2.4 Global Technology Convergence

2.5 Translation from/to Adjacent Industries

3.1 Emerging Opportunities for Preclinical Research Technologies

3.2 Enabling Science and Technology Developments

3.3 Medicinal Chemistry and Platform Chemistry Technologies

3.4 Organoids, Spheroids and 3D Self-Assembled Tissues

3.5 Biomimetic Sensors and Organ-on-Chip Devices

3.6 Animal Models Used in Research

3.7 Germline Gene Editing Tools and Stem Cells Reprogramming

3.8 Optical, Multimodality and Translational Imaging

4.1 Preclinical Disease Models Adoption Impact

4.2 Macro to Micro Visioning and Implications

4.3 Summary of Key Industry Drivers

4.4 Summary of Key Industry Challenges

4.5 Summary of Key Market Drivers and Restraints

4.6 Mapping of Key Market Drivers and Restraints

4.7 Technology Transfer Assessment and Perceptions

4.8 Open Innovation Avenues in preclinical disease models

5.1 Technology Maturity Level and Description

5.2 Roadmap Tapping into Technology Synergy

5.3 Business Model Hybridization

5.4 Approaches Driving Preclinical Disease Models

5.5 Technology Synergy Reshaping Value Chain

5.6 Future Perspective of Preclinical Technology

6.1 Funding and Investment Models and Adoption

6.2 Funding Contribution Focus

6.3 Preclinical Research Funding Trends

6.4 Private Investment Distribution by Type

6.5 Public Funding Distribution by Type

6.6 Public and Private Funding by Region

6.7 Public and Private Funding to Notice

7.1 Key Future Industry Trends

7.2 Levers for Growth in the Preclinical Space

7.3 Industry Dynamics in Drug Discovery

7.4 Regional Adoption Potential

7.5 Growth Opportunity Assessment

7.6 Preclinical Research Ecosystem

8.1 Companies to Watch per Technology Focus

8.2 major Innovations per Technology Segment

8.3 Medicinal Chemistry and Platform ChemistRy

8.4 Organoids, Spheroids and 3D Self-assemblies

8.5 Biomimetic Sensors and Organ-on-chip Devices

8.6 Animal Models Used in Research

8.7 Gene Editing and Stem Cells Reprogramming

8.8 Optical, Multimodal Translational Imaging

9.1 Key Industry Influencers

9.2 Key Industry Innovators

9.3 Key Industry Developers

9.4 Key Industry Referents

9.5 Key Industry Exemplars

10.1 NEW DEVELOPMENT PARTNERSHIPS IN 2019-2020

10.2 Collaboration agreements IN 2019-2020

10.3 Licensing Deals IN 2019-2020

10.4 Acquisitions and PARTNERSHIPS IN 2019-2020

10.5 Additional collaborations IN 2019-2020

Legal Disclaimer

The key focus of this research has been outlined as below: 1. Technology benchmarking and roadmap, market trends, capabilities, and applications targeted: Build a robust strategy by defining the universe of preclinical disease models opportunities and setting key priorities 2. Stakeholder activities, influence, industry initiatives: Evaluate opportunities by describing the main participants in the industry, analyzing potential outcomes and generating competitive intelligence 3. Investment environment and funding support: Support execution by connecting specific strategies with milestones, targets, owners, and deadlines based in funding and investments 4. Industry evolution and business analytics: Preclinical disease models overall industry evolution and business models
More Information
Deliverable Type Technology Research
No Index No
Podcast No
Author Cecilia Van Cauwenberghe
Industries Healthcare
WIP Number D98E-01-00-00-00
Is Prebook No